Biomed Central Ltd

SHERPA: Unknown

People

  1. Park
    Park
  2. Palomba
    Palomba
  3. Dahi
    Dahi
  4. Devlin
    Devlin
  5. Dogan
    Dogan
  6. Fei
    Fei
  7. Imber
    Imber
  8. Kalogirou Valtis
    Kalogirou Valtis
  9. Lin
    Lin
  10. Luttwak
    Luttwak

Groups

  1. Adult Leukemia (7)
  2. Center for Hematologic Malignancies (7)
  3. Department of Medicine (7)
  4. Hematologic Malignancies, Division of (7)
  5. GME, Medicine (3)
  6. Graduate Medical Education (3)
  7. Hematology-Oncology Fellows (3)
  8. Lymphoma (2)
  9. Biostatistics Service (1)
  10. Bone Marrow Transplant (1)
Search Within
  1. "Jae Park"
Formats
  1. Journal Article (5)
  2. Meeting Abstract (2)
Groups
  1. Adult Leukemia (7)
  2. Center for Hematologic Malignancies (7)
  3. Department of Medicine (7)
  4. Hematologic Malignancies, Division of (7)
  5. GME, Medicine (3)
  6. Graduate Medical Education (3)

More Groups

People
  1. Jae Park (7)
  2. Maria Palomba (2)
  3. Ahmet Dogan (1)
  4. Akshay Bedmutha (1)
  5. Alejandro Luna De Abia (1)
  6. Ana Alarcon Tomas (1)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (1)
  4. 2022 (2)
  5. 2020 (1)
  6. 2017 (1)
Publications
  1. Journal for ImmunoTherapy of Cancer (5)
  2. Journal of Hematology & Oncology (2)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALL
    Journal Article

    Culbert, A. A.; Gava, F.; Valtis, Y. K.; Satta, T.; Vora, S.; Rocco, J. M.; Nussenblatt, V.; Silbert, S. K.; Shalabi, H.; Yates, B.; more...
    Journal for ImmunoTherapy of Cancer (2025)

    Fulltext@MSK | Save
  • Conventional and novel [(18)F]FDG PET/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma
    Journal Article

    Leithner, D.; Flynn, J. R.; Devlin, S. M.; Mauguen, A.; Fei, T.; Zeng, S.; Zheng, J.; Imber, B. S.; Hubbeling, H.; Mayerhoefer, M. E.; more...
    Journal of Hematology & Oncology (2024)

    Fulltext@MSK | Save
  • Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
    Journal Article

    Shah, B. D.; Cassaday, R. D.; Park, J. H.; Houot, R.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Leguay, T.; Bishop, M. R.; Topp, M. S.; more...
    Journal for ImmunoTherapy of Cancer (2023)

    Fulltext@MSK | Save
  • Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
    Journal Article

    Shah, B. D.; Ghobadi, A.; Oluwole, O. O.; Logan, A. C.; Boissel, N.; Cassaday, R. D.; Leguay, T.; Bishop, M. R.; Topp, M. S.; Tzachanis, D.; more...
    Journal of Hematology & Oncology (2022)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: A preclinical model and initial clinical experience
    Journal Article

    Palomba, M. L.; Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Rivière, I.; Sadelain, M.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Concordance between healthcare providers and expert consensus recommendations in the management, monitoring, and mitigation of adverse events associated with CAR T-cell therapy: An updated analysis
    Meeting Abstract

    Frigault, M.; Cartwright, M.; Marcello, K.; Quill, T.; DeAngelo, D.; Galinsky, I.; Paul, S.; Park, J.
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study)
    Meeting Abstract

    DeAngelo, D. J.; Ghobadi, A.; Park, J. H.; Dinner, S. N.; Mannis, G. N.; Lunning, M. A.; Khaled, S. K.; Fathi, A. T.; Gojo, I.; Wang, E. S.; more...
    Journal for ImmunoTherapy of Cancer (2017)

    Fulltext@MSK | Save